Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) FCF Margin (2016 - 2025)

International Stem Cell (ISCO) has disclosed FCF Margin for 16 consecutive years, with 1.94% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 815.0% to 1.94% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.48%, a 245.0% decrease, with the full-year FY2024 number at 1.68%, down 1258.0% from a year prior.
  • FCF Margin was 1.94% for Q3 2025 at International Stem Cell, up from 13.57% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 23.85% in Q2 2023 to a low of 23.76% in Q1 2021.
  • A 5-year average of 1.06% and a median of 1.94% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -3487bps in 2021, then surged 2928bps in 2022.
  • International Stem Cell's FCF Margin stood at 17.69% in 2021, then skyrocketed by 118bps to 3.25% in 2022, then soared by 162bps to 8.52% in 2023, then tumbled by -136bps to 3.07% in 2024, then surged by 163bps to 1.94% in 2025.
  • Per Business Quant, the three most recent readings for ISCO's FCF Margin are 1.94% (Q3 2025), 13.57% (Q2 2025), and 10.43% (Q1 2025).